Cargando…

A glycosylated Fc‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide

AIM: To evaluate the pharmacokinetic and pharmacodynamic properties of a novel glycosylated Fc‐fused glucagon‐like peptide‐1(GLP‐1‐gFc) receptor agonist with distinctive receptor binding affinity, designed to improve in vivo stability and safety relative to the commercial GLP‐1 analogue dulaglutide,...

Descripción completa

Detalles Bibliográficos
Autores principales:	An, In Bok, Byun, Mi Sun, Yang, Sang In, Choi, Yuri, Woo, Jung Won, Jang, Hak Chul, Sung, Young Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383507/ https://www.ncbi.nlm.nih.gov/pubmed/32314505 http://dx.doi.org/10.1111/dom.14058

Ejemplares similares

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung, Tara, et al.
Publicado: (2015)

Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist
por: Quadri, Hamza, et al.
Publicado: (2021)

Comparison of the glucagon‐like‐peptide‐1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study
por: Singh, Priyamvada, et al.
Publicado: (2020)

Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study
por: Yale, Jean-François, et al.
Publicado: (2017)

Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide
por: Alatorre, Carlos, et al.
Publicado: (2017)

Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)

Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy
por: Roacho-Pérez, Jorge A., et al.
Publicado: (2021)

Localization of GTP-stimulated core glycosylation to fused microsomes
Publicado: (1983)

Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents
por: Kivell, Bronwyn M., et al.
Publicado: (2018)

Comparison of the Fc glycosylation of fetal and maternal immunoglobulin G
por: Einarsdottir, Helga K., et al.
Publicado: (2012)

Chemoenzymatic Fc Glycosylation via Engineered Aldehyde Tags
por: Smith, Elizabeth L., et al.
Publicado: (2014)

Fc-Linked IgG N-Glycosylation in FcγR Knock-Out Mice
por: Zaytseva, Olga O., et al.
Publicado: (2020)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Long‐Term Activation of Glucagon‐like peptide‐1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes
por: Xie, Saiyang, et al.
Publicado: (2022)

Mood After CPAP: Fewer Patients With Depression, but not Fewer With Anxiety
por: Marrone, Oreste
Publicado: (2019)

Necrotizing Pancreatitis Secondary to Dulaglutide Use
por: Bhat, Salman Zahoor, et al.
Publicado: (2021)

Engineered Fc-glycosylation switch to eliminate antibody effector function
por: Zhou, Qun, et al.
Publicado: (2020)

Antibody Fc Glycosylation Discriminates Between Latent and Active Tuberculosis
por: Lu, Lenette L, et al.
Publicado: (2020)

Sugar and spice: Fc glycosylation in antibody-mediated transplant rejection
por: Valenzuela, Nicole M.
Publicado: (2022)

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study
por: Miyagawa, J., et al.
Publicado: (2015)

Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)
por: Aschmoneit, Nadine, et al.
Publicado: (2022)

Fewer, Richer, Greener
por: Siegel, Laurence
Publicado: (2019)

Mode of administration of dulaglutide: implications for treatment adherence
por: Amblee, Ambika
Publicado: (2016)

Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes
por: Wang, Rijun, et al.
Publicado: (2021)

Exacerbation of atrial fibrillation related to dulaglutide use
por: Lee, Jayden, et al.
Publicado: (2021)

A Case of Dulaglutide-Induced Vaginal Bleed
por: Vaccaro, Christopher J, et al.
Publicado: (2023)

Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G
por: Fokkink, Willem Jan R., et al.
Publicado: (2015)

Role of N-Glycosylation in FcγRIIIa interaction with IgG
por: Van Coillie, Julie, et al.
Publicado: (2022)

Plasmacytoid Dendritic Cells Contribute to the Protective Immunity Induced by Intranasal Treatment with Fc-fused Interleukin-7 against Lethal Influenza Virus Infection
por: Kang, Moon Cheol, et al.
Publicado: (2017)

Older patients with persistent postural-perceptual dizziness exhibit fewer emotional disorders and lower vertigo scores
por: Zhang, Li, et al.
Publicado: (2022)

Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors
por: Isoda, Yuya, et al.
Publicado: (2015)

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study
por: Odawara, M., et al.
Publicado: (2016)

Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma
por: Kaye, Leanne, et al.
Publicado: (2022)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
por: Kim, Gwang Sil, et al.
Publicado: (2019)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Conformation Transition of Intracellular Part of Glucagon Receptor in Complex With Agonist Glucagon by Conventional and Accelerated Molecular Dynamics Simulations
por: Bai, Qifeng, et al.
Publicado: (2019)

Erratum: Plasmacytoid Dendritic Cells Contribute to the Protective Immunity Induced by Intranasal Treatment with Fc-fused Interleukin-7 against Lethal Influenza Virus Infection
por: Kang, Moon Cheol, et al.
Publicado: (2017)

Fc-fused IL-7 mobilizes long-term HSCs in a pro-B cell-dependent manner and synergizes with G-CSF and AMD3100
por: Kim, Sora, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ddfl082jmui8ri1n21ff762lek